**EHA RESEARCH GRANT AGREEMENT**

**EHA Executive Office** Koninginnegracht 12b 2514 AA The Hague The Netherlands

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxxx

This EHA Junior Research Grant Agreement (“**Agreement**”) is made and entered into by and between:

**UNDERSIGNED**:

**European Hematology Association**, an association under the laws of the Netherlands, registered under trade registry number 24334797, with its address at Koninginnegracht 12b, 2514 AA - The Hague, The Netherlands (“**EHA**”);

## AND

**Srdjan Grušanović**, Ústav molekulární genetiky AV ČR, v. v. i. (in English commonly referred to as the Institute of Molecular Genetics of the Czech Academy of Sciences), Laboratory of Haematooncol- ogy, Vídeňská 1083, 142 00, Prague 4, Czechia ("**Grantee**");

## AND

**Ústav molekulární genetiky AV ČR, v. v. i. (in English commonly referred to as the Institute of Molecular Genetics of the Czech Academy of Sciences)**, Laboratory of Haematooncology, Vídeňská 1083, 142 00, Prague 4, Czechia ("**Grantee Institute**").

Individually referred to as a “**Party**” and collectively as the “**Parties**”.

By applying for an EHA Junior Research Grant, the applicants and their institutes acknowledge and accept the conditions as set out in this Agreement.


**AGREED TERMS:**

**ARTICLE 1. ‘Grant and Purpose’**

EHA awards a Junior Research Grant of € 149,300 (Euros) to support the project “Effects of chronic inflammation on hematopoietic stem cell aging and response to infection” (“**Project**”), to be executed from 01 August 2025 to 31 July 2028. The grant funds shall be used solely in accordance with the approved budget and proposal (“**Annex 1**”).

## ARTICLE 2. ‘Financial Terms’

1. Grant funds will be transferred to the Grantee Institute, not to a personal account, according to the payment schedule (“**Annex 2**”), contingent on receipt and approval of the interim and final reports (“**Annex 3**”).



Docusign Envelope ID: 79BA982C-0097-47F4-B9FB-FE0A1677EB98

1. EHA will not fund overhead costs.
2. Any unused or misused funds must be returned to EHA upon request.
3. A separate account must be maintained for grant funds.
4. The Grantee and Grantee Institute shall notify EHA within thirty (30) days upon securing any additional project-related funding, including a statement describing its expected impact on the approved Project budget.

Page 1/6

Docusign Envelope ID: 79BA982C-0097-47F4-B9FB-FE0A1677EB98

1. Under no circumstance may costs related to the Project be reimbursed or charged more than once, including from EHA and/or other funding resources.

## ARTICLE 3. ‘Reporting’

1. Interim and final scientific reports and financial statements must be submitted according to the templates provided by EHA and on dates specified on the reporting schedule (“**Annex 3**”).
2. Interim and final financial statements must be signed by a finance officer at the Grantee In- stitute. The final financial statement must include an audited accounting signed off by an independent external auditor. The Grantee should reserve up to € 2,000 (Euros) in the Project budget for this purpose.
3. The Grantee agrees to submit annual impact reports to EHA’s impact measurement platform (e.g., Researchfish/Elsevier) during the grant period and for up to five (5) years following the end of the grant, and thereafter upon EHA’s request.
4. EHA may request interim updates during or after the Project for impact monitoring.
5. EHA reserves the right to review or audit the use of grant funds at any time during or within two years after the Project period.
6. The Grantee Institute shall retain all financial and project-related records for a period of at least five years after the end of the Project period and make them available to EHA upon request.

## ARTICLE 4. ‘Amendments’

Changes to the Project, including extensions, budget reallocations or institution changes, require prior written approval from EHA via an amendment request submitted at least 30 days in advance. Unap- proved changes may lead to repayment obligations.

## ARTICLE 5. ‘Acknowledgment and Publicity’

All Project outputs must acknowledge EHA support:

“Funding for this project was provided by an EHA Junior Research Grant awarded by the European

Hematology Association.”

Public announcements require prior approval from EHA. The Grantee agrees to cooperate in public visibility efforts. The Grantee shall not use EHA’s name, logo, or other trademarks in any communica- tion, including but not limited to press release, websites or promotional materials, without EHA’s prior written approval.

## ARTICLE 6. ‘Conduct and Compliance’

The Grantee Institute ensures that the Project complies with all applicable laws, ethics approvals, and safety regulations. The Grantee and Grantee Institute bear sole responsibility for research conduct.

## ARTICLE 7. ‘Data Protection’

All Parties shall comply with applicable data protection laws, including the GDPR. Each Party is an independent data controller and shall maintain confidentiality of shared personal data. Data breaches must be reported without undue delay.

Page 2/6

Docusign Envelope ID: 79BA982C-0097-47F4-B9FB-FE0A1677EB98

## ARTICLE 8. ‘Independent Status’

This Agreement does not create an employment, agency or joint venture relationship. Each Party remains fully independent and responsible for its obligations.

## ARTICLE 9. ‘Liability’

EHA is not liable for damages except in case of gross negligence or wilful misconduct by EHA’s man- agement. The Grantee and Grantee Institute shall indemnify EHA against third-party claims arising from the Project. EHA shall not be liable for any taxes, social security contributions, or other financial obligations arising from the grant.

## ARTICLE 10. ‘Confidentiality’

All Parties agree to keep confidential any non-public information obtained in connection with this Agreement, unless disclosure is required by law or with prior written consent of the other Party.

## ARTICLE 11. ‘Termination’

EHA may terminate this Agreement with immediate effect if:

1. the Project is discontinued or materially altered without approval;
2. misconduct, fraud or insolvency occurs;
3. the Grantee and/ or Grantee Institute breach this Agreement;
4. EHA becomes reasonably unable to make further payments for financial or organizational rea- sons.

Upon termination, EHA may require full or partial repayment. Termination does not affect obligations relating to reporting, confidentiality, data protection, or liability, which shall survive termination.

## ARTICLE 12. ‘Governing Law’

This Agreement is governed by Dutch law. All disputes shall be resolved exclusively by the District Court of The Hague, the Netherlands.

This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but such counterparts shall together constitute one and the same document.

Page 3/6

Docusign Envelope ID: 79BA982C-0097-47F4-B9FB-FE0A1677EB98

**IN WITNESS WHEREOF**:

The Parties hereto have executed this Agreement

for and on behalf of

## EUROPEAN HEMATOLOGY ASSOCIATION

**GRANTEE**

for and on behalf of

## GRANTEE

**INSTITUTE**

By: xxxxxxxxxxxxxxx

Position: EHA Managing Director Date:2025/06/26

Name: xxxxxxxxxxxxxxx

Position: Postdoctoral fellow

Date:2025/06/23

Name: xxxxxxxxxxxxxxx

Position: Director of the Institute Date: 2025/06/24